Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

Eligibility Criteria

• 1. Patient is 1 year to 21 years of age.
• 2. Patient has a diagnosis of AML, MDS, MDS/AML, MPAL, or JMML. Note: patients are allowed to have received a HMA or HDACi prior to undergoing alloHCT.
• 3. Patient has undergone allogeneic hematopoietic cell transplantation (no restrictions on conditioning regimen, donor or stem cell source, or GVHD prophylaxis regimen).
• 4. Patient and/or parent(s) or legal guardian(s) are capable of understanding the study, including potential benefits and risks, and sign written informed consent. Age-appropriate assent will be obtained.
• 5. Female patient of childbearing potential has a negative screening pregnancy test (urine or serum, as per local institutional standard).
• 6. Female patient with infant(s) agrees not to breastfeed her infant(s) while on study.
• 7. Patient of child-bearing potential (male and female) agrees to use effective method of contraception during the study.
• 1. Patient is enrolled on a clinical trial with investigational post-transplant medications. Note: trials involving defibrotide, post-transplant cyclophosphamide, and Lactobacillus plantarum are permitted. Other trials involving investigational medications that aren't leukemia or GVHD-directed may also be permitted after consultation with the overall PI.
• 2. Patient has a planned administration of non-protocol chemotherapy, radiation therapy, donor leukocyte infusion, or immunotherapy during the planned study period.
• 3. Patient has a known allergy to azacitidine or vorinostat.
• 4. Patient has chronic myelogenous leukemia.
• 5. Concomitant use of coumarin-derived anticoagulants or valproic acid.